Kaleido Biosciences Inc Quick Ratio (KLDO) starting from the fourth quarter 2021 to fourth quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kaleido Biosciences Inc   (NASDAQ: KLDO)

Kaleido Biosciences Inc 's Quick Ratio

KLDO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2021, Quick Ratio fell to 1.76 a new company low.

Within Biotechnology & Pharmaceuticals industry 163 other companies have achieved higher Quick Ratio than Kaleido Biosciences Inc in fourth quarter 2021. While Quick Ratio total ranking in the fourth quarter 2021 has deteriorated compared to the prior quarter from 572 to 2061.

Explain Quick Ratio?
How much Cash & cash equivalents KLDO´s has?
What are KLDO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KLDO Quick Ratio (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2		 (Mar 31 2021)
Q1		 (Dec 31 2020)
Q4
Y / Y Current Liabilities Change 171.89 % 145.51 % 79.51 % 485.87 % 297.97 %
Y / Y Cash & cash equivalent Change -16.76 % 2.06 % 1.33 % 71.66 % -35.12 %
Quick Ratio MRQ 1.76 4.45 11.31 12.88 5.76
KLDO's Total Ranking # 2061 # 572 # 503 # 992 #
Seq. Current Liabilities Change 74.29 % 96.73 % -11.28 % -10.62 % 57.38 %
Seq. Cash & cash equivalent Change -30.87 % -22.68 % -22.07 % 99.82 % -15.24 %



Quick Ratio fourth quarter 2021 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 164
Healthcare Sector # 870
Overall Market # 2061


Quick Ratio Statistics
High Average Low
49.05 22.15 1.76
(Sep 30 2019)   (Dec 31 2021)




Financial Statements
Kaleido Biosciences Inc 's Current Liabilities $ 22 Millions Visit KLDO's Balance sheet
Kaleido Biosciences Inc 's Cash & cash equivalent $ 38 Millions Visit KLDO's Balance sheet
Source of KLDO's Sales Visit KLDO's Sales by Geography


Cumulative Kaleido Biosciences Inc 's Quick Ratio

KLDO's Quick Ratio for the trailling 12 Months

KLDO Quick Ratio

 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months		 (Dec 31 2020)
12 Months
Y / Y Current Liabilities TTM Growth 167.56 % 186.75 % 215.77 % 133.85 % 42.61 %
Y / Y Cash & cash equivalent TTM Growth 14.58 % 6.23 % -4.42 % -13.75 % -39.65 %
Quick Ratio TTM 5.4 7.81 9.95 11.08 12.61
Total Ranking TTM # 5432 # 5335 # 653 # 273 #
Seq. Current Liabilities TTM Growth 40.48 % 27.83 % 11.82 % 33.24 % 50.56 %
Seq. Cash & cash equivalent TTM Growth -2.91 % 0.42 % 0.36 % 17.09 % -9.98 %

Quick ratio ranking by company, industry and sector >> Back to KLDO Financial Strength Comparisons >> Go to Compare KLDO Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q4 2021 to $21.81 millions, cumulative Quick Ratio decreased to 5.4 below the Kaleido Biosciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 186 other companies have achieved higher Quick Ratio than Kaleido Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2021 from 5335 to 5432.

Explain Quick Ratio?
How much Cash & cash equivalents KLDO´s has?
What are KLDO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 187
Healthcare Sector # 1176
Within the Market # 5432


trailing twelve months Quick Ratio Statistics
High Average Low
9.09 5.44 3.31
(Dec 31 2019)   (Jun 30 2019)




Companies with similar Quick Ratio in the quarter ending Dec 31 2021, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2021 MRQ Cash & cash equivalentDec 31 2021 MRQ Current Liabilities
Coherus Oncology inc   4.83 $ 417.195  Millions$ 86.300  Millions
Poseida Therapeutics Inc   4.76 $ 206.325  Millions$ 43.335  Millions
Palisade Bio Inc   4.57 $ 10.495  Millions$ 2.297  Millions
Argenx Se  4.55 $ 1,334.676  Millions$ 293.415  Millions
Sutro Biopharma Inc   4.41 $ 160.757  Millions$ 36.418  Millions
Prokidney Corp   4.37 $ 20.558  Millions$ 4.709  Millions
Cyclo Therapeutics Inc   4.36 $ 16.613  Millions$ 3.812  Millions
Exelixis Inc   4.35 $ 1,467.074  Millions$ 337.590  Millions
Eloxx Pharmaceuticals Inc   4.25 $ 42.268  Millions$ 9.955  Millions
Polarityte Inc   4.18 $ 19.375  Millions$ 4.635  Millions
Precision Biosciences Inc  3.99 $ 143.663  Millions$ 35.980  Millions
Vericel Corporation  3.97 $ 103.398  Millions$ 26.052  Millions
Old Ayala Inc   3.94 $ 36.982  Millions$ 9.382  Millions
Scholar Rock Holding Corp  3.93 $ 252.994  Millions$ 64.297  Millions
Apeiron Capital Investment Corp   3.93 $ 0.752  Millions$ 0.191  Millions
Greenlight Biosciences Holdings Pbc  3.85 $ 31.446  Millions$ 8.170  Millions
Atyr Pharma Inc   3.82 $ 107.911  Millions$ 28.245  Millions
Seagen Inc   3.80 $ 2,160.036  Millions$ 568.854  Millions
Cellectis S a   3.76 $ 185.636  Millions$ 49.348  Millions
Genetic Technologies Limited  3.54 $ 9.806  Millions$ 2.771  Millions
Atara Biotherapeutics Inc   3.51 $ 371.068  Millions$ 105.786  Millions
Regenxbio Inc   3.51 $ 457.439  Millions$ 130.472  Millions
Brainstorm Cell Therapeutics inc   3.50 $ 22.094  Millions$ 6.317  Millions
Biocardia Inc   3.47 $ 12.872  Millions$ 3.712  Millions
Immunocore Holdings Plc  3.40 $ 334.149  Millions$ 98.146  Millions
Eiger Biopharmaceuticals Inc   3.40 $ 106.077  Millions$ 31.223  Millions
Codiak Biosciences Inc   3.14 $ 76.938  Millions$ 24.504  Millions
Armata Pharmaceuticals Inc   3.11 $ 10.288  Millions$ 3.305  Millions
Pharmacyte Biotech Inc   3.04 $ 2.202  Millions$ 0.725  Millions
Zivo Bioscience Inc   3.02 $ 8.905  Millions$ 2.948  Millions

Date modified: 2026-09-08T15:10:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.